Press release
Glioblastoma Multiforme Drugs Market USD 785 Million by 2020
Visit the Glioblastoma Multiforme Drugs Market 2013-2020 report https://www.ihealthcareanalyst.com/report/glioblastoma-multiforme-drugs-market/
The global Glioblastoma multiforme drugs market segmentation is based on drug types (Bevacizumab, Temozolomide, Carmustine). The global Glioblastoma multiforme drugs market report provides market size (Revenue USD Million 2013 to 2020), market share, market trends and forecasts growth trends (CAGR%, 2016 to 2020).
Glioblastoma multiforme (GBM), also known as glioblastoma and grade IV astrocytoma, is the most common and most aggressive cancer that begins within the brain. Uncommon risk factors include genetic disorders such as neurofibromatosis and Li Fraumeni syndrome and previous radiation therapy. Typically, treatment involves surgery after which chemotherapy and radiation therapy is used. The medication temozolomide is frequently used as part of chemotherapy, whereas high dose steroids are used to help reduce swelling and decrease symptoms.
The global Glioblastoma multiforme drugs market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
1.Drug Type
1.1 Bevacizumab (Avastin)
1.2 Temozolomide
1.3 Carmustine (BiCNU)
2. Geography (Region, Country)
2.1 North America (U.S., Canada)
2.2 Latin America (Brazil, Mexico, Rest of LA)
2.3 Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
2.4 Asia Pacific (Japan, China, India, Rest of APAC)
2.5 Rest of the World
3. Company Profiles
3.1 AbbVie, Inc.
3.2 Activates GmbH
3.3 Agenus Inc.
3.4 Arog Pharmaceuticals, Inc.
3.5 Bristol-Myers Squibb Company
3.6 Cavion LLC
3.7 Celled Therapeutics Inc.
3.8 CTI BioPharma Corporation
3.9 Cortice Bioscience Inc.
3.10 Eisai Co., Ltd.
3.11 Exelixis Inc.
3.12 F.Hoffman-La Roche Ltd.
3.13 Peregrine Pharmaceuticals, Inc.
3.14 OncoSynergy
3.15 Merrimack Pharmaceuticals, Inc.
iHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas.
Ana Aitawa
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Phone: (314) 736-9294.
Email: sales@ihealthcareanalyst.com
https://www.ihealthcareanalyst.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Glioblastoma Multiforme Drugs Market USD 785 Million by 2020 here
News-ID: 376411 • Views: …
More Releases from iHealthcareAnalyst, Inc.
Global Amyotrophic Lateral Sclerosis Devices Market $19.5 Billion by 2029
The global market for amyotrophic lateral sclerosis devices or motor neuron disease devices anticipated to reach $19.5 billion by 2029, growing at a CAGR of 7.3% over the forecast period, driven by increasing incidence, rising geriatric population, lack of curative treatment, growing public awareness, and technological advancements in palliative care.
https://www.ihealthcareanalyst.com/global-amyotrophic-lateral-sclerosis-devices-market/
Amyotrophic lateral sclerosis or Lou Gehrig's disease or motor neuron disease (MND) is characterized by progressive degeneration of the motor nerve…
Global Blood Gas Monitoring Products Market Growing at CAGR of 6.2% to Reach $5. …
The global market for blood gas monitoring products is estimated to reach $5.5 billion by the end of 2025, expanding at a CAGR of 6.2% during the forecast period, supported by growing geriatric population, rising prevalence of chronic diseases, and technological advances.
The global blood gas monitoring devices market research report provides market size (Revenue US$ Million 2017 to 2025), market share analysis, growth trends and forecast (CAGR%, 2019 to 2025).…
Advances in Mobile Connectivity Services to Drive Telemedicine Technologies and …
According to a new market research report Telemedicine Technologies and Services Market 2015-2023 published by iHealthcareAnalyst, Inc., the global computer-aided detection market to reach US$ 73.2 Billion by 2023, expanding at a CAGR of 13.5% from 2018-2023.
Visit the Global Telemedicine Technologies and Services Market Analysis and Forecast 2018-2023 report at https://www.ihealthcareanalyst.com/report/telemedicine-technologies-services-market/
The global telemedicine technologies and services market newly published (updated 2018) report estimates the market size (US$ million 2015-2023)…
Global Internet Pharmacies Market to Cross US$ 100 Billion by 2023
The global internet pharmacies market is estimated to reach US$ 106 Billion by 2023, growing at a CAGR of 15.7% over the forecast period, driven by rising personal disposable income, lower prices, surge in internet penetration, stupendous growth of online retail market and a large number of online players entering the online healthcare product segment.
The major players are in a race to increase their share in the industry by…
More Releases for Glioblastoma
Understanding Impact of COVID-19 on Glioblastoma Multiforme (GBM) Market
Glioblastoma Multiforme (GBM), also known as glioblastoma, is a form of brain cancer. It is a rapidly-growing glioma that develops from star-shaped glial cells, such as oligodendrocytes and astrocytes that support the nerve cells in the brain. GBM is also called as grade IV astrocytoma and is among the most invasive forms of glial tumors. It is a fast-growing and aggressive form of tumor in the central nervous system (CNS)…
2019 - 2025 Glioblastoma Multiforme Treatment Market | GBM Market
Global Glioblastoma Multiforme Treatment Market, Its Market Trends And Analysis
Glioblastoma multiforme is the high-grade glioma and potent malignant brain tumor that affects glial cells. Glioblastoma multiforme contains the complexly differentiated neoplastic astrocytes which are the subtype of central nervous system. Glioblastoma multiforme is different from the anaplastic astrocytoma due to the presence of hyperplastic blood vessels and necrotic tissue.
Request Sample Report:
https://precisionbusinessinsights.com/request-sample?product_id=16248
The global glioblastoma multiforme treatment market is…
Glioblastoma Treatment Drugs Market : Drivers, Restraint & Future Growth
Brain tumors is one of the leading cause of cancer which is common among children and teenagers. Glioblastoma (GBM) is most common grade four tumor, is malignant and contains dead tumor cells. It is also called as Glioblastoma multiforme, it has variants of giant cell Glioblastoma and gliosarcoma found in cerebral hemisphere of brain. The exact cause of this tumor is not known but is also found in spinal cord…
Glioblastoma Multiforme Treatment Market : Global Glioblastoma Multiforme Treatm …
Glioblastoma Multiforme Treatment Market
Precision Business Insights (PBI) in its report titled “Global Glioblastoma Multiforme Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2017 and Forecast 2018-2027” assesses the market performance over 2018-2027. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period.
Glioblastoma multiforme is the high-grade glioma and…
Glioblastoma Multiforme Pipeline Review H1 2017
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2017, provides an overview of the Glioblastoma Multiforme (GBM) (Oncology) pipeline landscape.
Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor. GBMs arise from glial cells, which are cells that form the tissue that surrounds and protects other nerve cells found within the brain and spinal cord. GBMs are mainly composed of star-shaped glial…
Glioblastoma Multiforme Treatment (GBM) Industry Analysis by Segments
Glioblastoma multiforme (GBM) is a high-grade gliomas and the most malignant astrocytic tumor, composed of complexly differentiated neoplastic astrocytes, a subtype of central nervous system (CNS). Glioblastoma is clinically classified as grade IV astrocytoma and differs from anaplastic astrocytoma (grade III) due to the presence of necrotic tissue and hyperplastic blood vessels. The diagnosis of GBM is carried out with imaging modules such as computed tomography (CT), magnetic resonance imaging…
